McGrath SE - Search Results

1

McGrath SE, Michael A, Morgan R, Pandha H. McGrath SE, et al. Adv Clin Chem. 2015;71:47-76. doi: 10.1016/bs.acc.2015.06.002. Epub 2015 Jul 21. Adv Clin Chem. 2015. PMID: 26411411 Review.

2

Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.

McGrath SE, Annels N, Madhuri TK, Tailor A, Butler-Manuel SA, Morgan R, Pandha H, Michael A. McGrath SE, et al. BMC Cancer. 2018 Oct 3;18(1):943. doi: 10.1186/s12885-018-4816-5. BMC Cancer. 2018. PMID: 30285763 Free PMC article.

3

Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.

Annels NE, Simpson GR, Denyer M, McGrath SE, Falgari G, Killick E, Eeles R, Stebbing J, Pchejetski D, Cutress R, Murray N, Michael A, Pandha H. Annels NE, et al. Among authors: mcgrath se. Clin Exp Immunol. 2014 Aug;177(2):428-38. doi: 10.1111/cei.12332. Clin Exp Immunol. 2014. PMID: 24654775 Free PMC article.

4

Engrailed homeobox transcription factors as potential markers and targets in cancer.

McGrath SE, Michael A, Pandha H, Morgan R. McGrath SE, et al. FEBS Lett. 2013 Mar 18;587(6):549-54. doi: 10.1016/j.febslet.2013.01.054. Epub 2013 Feb 7. FEBS Lett. 2013. PMID: 23395604 Free article. Review.

5

EN2: a novel prostate cancer biomarker.

McGrath SE, Michael A, Morgan R, Pandha H. McGrath SE, et al. Biomark Med. 2013 Dec;7(6):893-901. doi: 10.2217/bmm.13.115. Biomark Med. 2013. PMID: 24266821 Review.

6

The prognostic significance of specific HOX gene expression patterns in ovarian cancer.

Kelly Z, Moller-Levet C, McGrath S, Butler-Manuel S, Kavitha Madhuri T, Kierzek AM, Pandha H, Morgan R, Michael A. Kelly Z, et al. Int J Cancer. 2016 Oct 1;139(7):1608-17. doi: 10.1002/ijc.30204. Epub 2016 Jun 14. Int J Cancer. 2016. PMID: 27225067 Free article.

7

Low grade serous ovarian carcinoma with metastases to the sternum and ribs.

McGrath S, Madhuri TK, Susarla S, Haagsma B, Saleh F, Michael A. McGrath S, et al. Pathology. 2012 Aug;44(5):481-2. doi: 10.1097/PAT.0b013e3283559d7d. Pathology. 2012. PMID: 22744167 No abstract available.

8

Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion.

McGrath SE, Webb A, Walker-Bone K. McGrath SE, et al. J Clin Oncol. 2013 Feb 1;31(4):e51-2. doi: 10.1200/JCO.2012.43.2872. Epub 2012 Dec 26. J Clin Oncol. 2013. PMID: 23270004 No abstract available.

9

Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience.

Battisti NML, True V, Chaabouni N, Chopra N, Lee K, Shepherd S, Shapira-Rotenberg T, Joshi R, McGrath S, Okines A, Parton M, Turner N, Mohammed K, Allen M, Johnston S, Ring A. Battisti NML, et al. Breast Cancer Res Treat. 2020 Jan;179(1):101-111. doi: 10.1007/s10549-019-05444-0. Epub 2019 Sep 18. Breast Cancer Res Treat. 2020. PMID: 31535318

10

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.

Cunningham N, Shepherd S, Mohammed K, Lee KA, Allen M, Johnston S, Kipps E, McGrath S, Noble J, Parton M, Ring A, Turner NC, Okines AFC. Cunningham N, et al. Breast Cancer Res Treat. 2022 Oct;195(3):333-340. doi: 10.1007/s10549-022-06703-3. Epub 2022 Aug 17. Breast Cancer Res Treat. 2022. PMID: 35976513 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page